What’s Next For Guilty GlaxoSmithKline plc?

GlaxoSmithKline plc (LON: GSK) has been fined after being found guilty of bribery but what’s next for the company.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKlineFor GlaxoSmithKline’s (LSE: GSK) (NYSE: GSK.US) shareholders, the wait is finally over. It was announced today that the company has been fined £300m after being found guilty of bribery by a Chinese court.

In some respects this is great news. Indeed, although the fine is the biggest such penalty levied on foreign a company in China, it removes much uncertainty, bringing to an end 15 months of speculation.

Alongside the fine, the former head of Glaxo’s China business, Mark Reilly pleaded guilty to bribery-related charges and was given a three-year suspended sentence. He will be deported back to the UK.

Not over yet

Still, despite this ruling from China, Glaxo could face further action at a corporate level from US and UK authorities.

UK and US authorities have the power to punish the company for overseas corruption and investigations are under way in both countries. The guilty verdict from China will definitely have a negative outcome on the investigations by agencies in the West.

However, for a company like Glaxo, which reported pre-tax profits of £6.6bn last year, the company should have no trouble paying fines resulting from guilty verdicts.

Changing habits

The Chinese bribery scandal has been a wake-up call for Glaxo. The company is now working hard to change the way that it does business, formally reforming its incentive programme for marketing employees. Now, sales staff are no longer paid according to sales targets hit and the company has stopped paying doctors to speak on its behalf at medical conferences.

The group is also continuing its work within China, supporting the government’s healthcare reform agenda and the company’s Chinese business is showing some signs of a return to normality. In particular, Chinese sales declines are already slowing after bribery revelations, Chinese revenue plunged 61% during the third quarter of 2013. This decline has since moderated, with sales only declining by around 20% during the first half of 2014.

Plenty to look forward to

Away from the Chinese issues, Glaxo is in rude health and the company has, according to City analysts, one of the best pipelines of new treatments underdevelopment within its sector. Specifically, Glaxo currently has 40 new drugs under development, including a vaccine for the deadly Ebola virus currently sweeping West Africa.

Additionally, Glaxo has built up a world leading consumer healthcare company. The group signed a deal with peer Novartis earlier this year, which will see Glaxo and Novartis create a new Consumer Healthcare business, with 2013 pro forma revenues of £6.5 billion. Glaxo will own the lion’s share of this business, with a 63.5% equity interest.

So, Glaxo is moving forward, and with the Chinese bribery issue behind it, the company can get on with developing its treatment portfolio and consumer healthcare arm.

A great pick

Due to its position in the world healthcare market, Glaxo is a defensive by nature, which makes the company the perfect long term ‘buy and forget’ share. And with a dividend yield of 5.4% at current levels, it’s hard to ignore the company.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »